ARCUS genome editing platform with in vivo programs PBGENE-HBV (chronic hepatitis B) and PBGENE-DMD (Duchenne muscular dystrophy); azer-cel (azercabtagene zapreleucel) Phase 1 in progressive MS via TG Therapeutics partnership
No detailed funding rounds available.
Total known funding: